SAN FRANCISCO, May 10, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Helix BioPharmaCorporation (AMEX: HBP, TSX: HBP) ("the Company") with a twelve month target price of $6.20. Ross Silver, Principal Analyst at Vista Partners stated, "The Company is developing products
To download a FREE copy of the Helix BioPharma Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
Contact:877.215.4813 or firstname.lastname@example.org
SOURCE Vista Partners
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All